Lv4
520 积分 2022-10-26 加入
An update on the importance of plasma protein binding in drug discovery and development
15小时前
已完结
Discovery of MD-265: A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia
1个月前
已完结
Development and Validation of a Cell-Based Binding Neutralizing Antibody Assay for an Antibody–Drug Conjugate
1个月前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
2个月前
已完结
Concentration-dependent plasma protein binding: Expect the unexpected
3个月前
已完结
Degrader–Antibody Conjugates: Emerging New Modality
3个月前
已完结
Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer
4个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
5个月前
已完结
ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)
9个月前
已完结
Preclinical studies of the bispecific MUC1xEGFR antibody drug conjugate M1231 in EGFR mutant NSCLC
10个月前
已完结
皖公网安备34019202002308
